Reducing breathing issues from lung radiation in people with ILD
Treatments studied
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This trial tests whether a combination of two medications (dexamethasone and N-acetyl cysteine) can reduce breathing problems caused by radiation to lung tumors in patients who have both lung cancer and fibrotic interstitial lung disease (ILD). It aims to find a better way to manage side effects from radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer or 1-2 lung tumors that have spread from another cancer, and you are going to get high-dose radiation to cure or control it.
- You have a type of lung scarring called fibrotic interstitial lung disease (ILD), confirmed by a lung specialist.
- You are age 18 or older, and your life expectancy is more than 6 months.
- You are not taking steroids (like prednisone) by mouth or IV, and you haven't had radiation to the lungs before.
- You are not pregnant or breastfeeding, and you can use effective birth control if needed.
- You are not taking N-acetyl cysteine (NAC) now or recently, and you have no allergies or conditions that would make dexamethasone or NAC unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether two different doses of duloxetine and amitriptyline can reduce coughing caused by interstitial lung disease (ILD). If you have had a long-lasting ILD-related cough despite stable ILD treatment, this trial may help find a better way to control your cough.
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This study uses analysis of mucus (sputum) to guide treatment with the goal of reducing long-lasting cough in adults with interstitial lung disease (ILD). You may be asked to provide sputum samples and may receive treatment decisions based on those results.
This trial tests a drug called nintedanib to see if it can prevent radiation-related lung inflammation (pneumonia) in people with lung cancer that cannot be surgically removed. It may help protect your lungs during radiation treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.